Mold allergy is one of the most underdiagnosed forms of indoor allergen sensitization in the United States. Unlike pollen allergies — which have clear, predictable seasonal windows tied to plant reproductive cycles — mold allergies operate on a fundamentally different biological timeline. Outdoor mold spore counts peak in late summer and fall, but indoor mold can release allergenic spores year-round at concentrations that exceed outdoor levels by orders of magnitude in affected buildings. The American Academy of Allergy, Asthma & Immunology (AAAAI) estimates that 10–25% of atopic individuals are sensitized to at least one mold allergen, and that sensitization to Alternaria alternata is an independent risk factor for severe, potentially fatal asthma attacks.
This guide is written for people experiencing respiratory, skin, or systemic symptoms that worsen in certain indoor environments, people with confirmed mold allergy seeking to understand their sensitization pattern and treatment options, and clinicians and allied health professionals seeking a consolidated clinical and environmental reference.
Both mold allergy and pollen allergy are IgE-mediated hypersensitivity reactions — the immune system produces antigen-specific IgE antibodies that bind to mast cells and basophils, triggering degranulation and histamine release upon re-exposure to the allergen. However, the two differ in important ways that affect diagnosis, management, and prognosis.
Source organism: Pollen is produced by seed plants (trees, grasses, weeds) with brief, well-defined pollination seasons. Fungi produce spores as part of their normal growth cycle year-round, with seasonal peaks that vary by species. A single mold colony can shed millions of spores per day over months.
Particle size: Tree pollen grains range from 20–100 microns in diameter — large enough to be trapped by nasal hair in the upper airway, producing rhinitis predominantly. Mold spores range from 2–20 microns, with some species producing conidia as small as 1–2 microns. Small spores penetrate to the lower respiratory tract, making mold allergy significantly more likely to trigger bronchospasm, asthma exacerbations, and alveolar inflammation.
Indoor vs outdoor exposure: Pollen allergy is primarily an outdoor exposure problem. Mold allergy has a major indoor exposure component. Homes with active mold growth — in bathrooms, basements, crawl spaces, or HVAC systems — maintain continuous high-concentration allergen exposure regardless of outdoor conditions or season. This is why mold-sensitized individuals often report symptom improvement during vacations but immediate recurrence upon returning home.
Allergen complexity: Pollen allergens are typically a handful of well-characterized proteins per species. Fungi produce dozens of distinct allergenic proteins across multiple cellular fractions — cell wall components, secreted enzymes, intracellular proteins — making cross-reactivity between mold species and between molds and other allergens (latex, foods) clinically significant.
Not all mold species are equally allergenic. Allergic sensitization requires that a mold species produce proteins capable of inducing IgE antibody formation in susceptible individuals (atopic genotype), and that human exposure to these proteins be sufficient to cross the sensitization threshold. The clinically most significant mold allergens are:
Alternaria is the mold allergen most strongly linked to severe asthma. Its major allergen, Alt a 1, is an exceptionally potent IgE inducer. Sensitization rates in asthmatic populations reach 30–40% in certain geographic regions. Outdoor Alternaria spore counts peak July through October in temperate climates, corresponding to the period of highest asthma emergency department visits. Indoor Alternaria colonizes window sills, air conditioner drip pans, potted plant soil, and food — particularly tomatoes, peppers, and citrus.
Cladosporium produces the largest outdoor spore counts of any mold genus worldwide — a single square meter of colonized leaf litter can release 50 million spores per day. Its primary allergen, Cla h 8, shows cross-reactivity with Alternaria (Alt a 1) in approximately 30% of sensitized patients, a phenomenon called co-sensitization or cross-reactivity that can complicate allergy test interpretation. Cladosporium thrives on window sills, painted surfaces, and dead plant material indoors.
These two genera are clinically grouped together because their spores are morphologically similar (1–3 micron conidia) and share several cross-reactive allergens. Aspergillus fumigatus sensitization is particularly serious because this species is also capable of causing invasive infection in immunocompromised individuals — a condition called allergic bronchopulmonary aspergillosis (ABPA) in susceptible asthmatic patients. ABPA is characterized by mucoid impaction, bronchiectasis, and progressive lung damage if untreated. Penicillium and Aspergillus are the dominant indoor mold species found in water-damaged buildings.
The IgE-mediated allergic significance of Stachybotrys is more limited than popular media coverage suggests, because its large spores (6–12 microns) are not easily aerosolized under normal conditions. However, its mycotoxins (trichothecenes, satratoxins) cause non-IgE-mediated toxic effects on respiratory epithelium and immune cells at concentrations far below those required for IgE sensitization. Individuals with Stachybotrys exposure often experience symptoms that do not fit a classic IgE allergy pattern — they may have negative allergy tests while still having significant inflammation-based illness. See our mold and asthma guide for the distinction between allergic and toxic mold-related lung disease.
| Allergen | Peak Season | Primary Location | IgE Prevalence | Key Symptoms | Avoidance Strategy | Immunotherapy Available |
|---|---|---|---|---|---|---|
| Alternaria mold | July–October (outdoor); Year-round (indoor) | Outdoor leaf litter; indoor window sills, AC drip pans, food | 30–40% of asthmatics | Severe asthma, rhinitis, anaphylaxis risk | HEPA filtration; source mold remediation; avoid composting areas | Yes — SCIT effective; SLIT limited evidence |
| Cladosporium mold | Peak summer/fall (outdoor); Year-round (indoor) | Outdoor plants, soil; indoor painted surfaces, window sills | 15–25% of atopic adults | Rhinitis, conjunctivitis, mild–moderate asthma | Reduce outdoor exposure in peak season; indoor humidity <50% | Yes — SCIT; cross-reactive with Alternaria extracts |
| Aspergillus / Penicillium mold | Year-round (indoor dominant) | Water-damaged drywall, HVAC ducts, crawl spaces, bathrooms | 10–20% of atopic individuals; ABPA 1–2% of asthmatics | Rhinitis, asthma, ABPA (Aspergillus); cough, wheeze | Source remediation critical; antifungal therapy for ABPA | Yes — SCIT for allergic rhinitis; antifungals for ABPA |
| Stachybotrys (black mold) | Year-round (chronic moisture sites) | Flooded drywall, subfloors, ceiling tiles with chronic leaks | Low IgE sensitization; high toxic/inflammatory response | Fatigue, headache, respiratory irritation, hemorrhage (rare) | Source removal essential; no occupancy during remediation | No specific SCIT; toxin effects require source elimination |
| Dust mites | Year-round (peak in warm, humid months) | Bedding, carpets, upholstered furniture, stuffed toys | 20–30% of atopic individuals; most common indoor allergen | Perennial rhinitis, eczema, asthma | Allergen-proof mattress/pillow covers; wash bedding >130°F | Yes — SCIT and SLIT both well-established |
| Pet dander (cat/dog) | Year-round | All surfaces in pet-occupied home; persists 6+ months post-removal | 15–30% of atopic population | Rhinitis, asthma, conjunctivitis; rapid onset on exposure | Remove pet or restrict to certain rooms; HEPA filtration; frequent bathing | Yes — SCIT highly effective; SLIT emerging |
| Cockroach allergen | Year-round (urban housing) | Kitchen, bathroom, basement in multi-family housing | 40–60% of inner-city asthmatic children | Severe persistent asthma; rhinitis less prominent | Integrated pest management; seal food containers; moisture control | Yes — SCIT; evidence base growing; SLIT in development |
SCIT = Subcutaneous Immunotherapy (allergy shots); SLIT = Sublingual Immunotherapy (drops/tablets); ABPA = Allergic Bronchopulmonary Aspergillosis. Prevalence figures from AAAAI, EAACI, and NIAID published data.
Cross-reactivity occurs when IgE antibodies raised against one allergen protein recognize structurally similar proteins in a different allergen source. In mold allergy, cross-reactivity has important clinical implications. The most well-documented mold cross-reactions include:
Cross-reactivity also explains why some mold-sensitized patients improve symptomatically after mold source elimination even if their predominant clinical sensitization appears to be to a non-mold allergen. For skin and immune system effects of mold exposure, see our mold and eczema guide and mold and sinuses guide.
Alternaria sensitization, in particular, has been associated with "thunderstorm asthma" events — sudden, severe bronchospasm triggered by high outdoor mold spore concentrations during meteorological events that rupture fungal spore clusters into ultra-fine respirable particles. Multiple deaths from thunderstorm asthma events have been documented in Australia and the UK. Individuals with known Alternaria sensitization and asthma should carry an epinephrine auto-injector (EpiPen) and have an emergency asthma action plan in place before peak mold season.
Two primary diagnostic tools exist for confirming IgE-mediated mold sensitization: skin prick test (SPT) and serum-specific IgE (ssIgE) blood test (formerly called RAST, now commonly performed as ImmunoCAP assay by Thermo Fisher or ALEX test by Macro Array Diagnostics).
SPT involves applying a small quantity of standardized mold allergen extract to the forearm skin via a lancet prick. A wheal (raised bump) >3 mm larger than the negative control after 15 minutes indicates IgE-mediated sensitization. SPT is considered the gold standard for inhalant allergy diagnosis because it has high sensitivity (80–90% for well-standardized extracts), provides immediate results, and is relatively inexpensive. However, its accuracy depends critically on the quality of the allergen extract used — mold extracts are notoriously difficult to standardize due to variable protein content, proteolytic degradation, and lot-to-lot variability. Results can vary significantly between testing facilities.
ssIgE assays measure circulating IgE antibodies directed against specific mold allergen components in a blood sample. Modern component-resolved diagnostics (CRD) panels can identify sensitization to individual mold allergen proteins (Alt a 1, Asp f 1, Cla h 8) rather than whole mold extracts, providing greater diagnostic specificity. ssIgE testing is preferred when: the patient takes antihistamines that cannot be discontinued; the patient has severe atopic dermatitis making skin testing unreliable; or previous SPT has been equivocal. Results are reported as allergen-specific IgE levels in kU/L with Class 0–6 scoring; Class ≥2 (0.35–0.70 kU/L) is generally considered clinically significant.
For patients whose symptoms suggest mold exposure but whose allergy tests are negative, environmental investigation is warranted — mycotoxin effects, nonspecific inflammatory responses to beta-glucans in mold cell walls, and irritant effects from volatile organic compounds released by growing mold are all symptom-producing mechanisms that operate outside the IgE pathway. See our DIY mold testing guide and air purifiers for mold guide for environmental assessment options.
Allergen immunotherapy (AIT) is the only disease-modifying treatment for IgE-mediated allergy. Unlike antihistamines and corticosteroid nasal sprays — which suppress symptoms during ongoing allergen exposure — AIT induces immunological tolerance, gradually reducing IgE sensitization and shifting the immune response toward a tolerogenic phenotype. The mechanism involves induction of allergen-specific regulatory T cells (Tregs) and IgG4 blocking antibodies that compete with IgE for allergen binding.
SCIT for mold allergy involves injecting progressively increasing doses of mold allergen extract subcutaneously, typically weekly during a build-up phase (4–6 months), followed by monthly maintenance injections for 3–5 years. Evidence for SCIT with Alternaria and Cladosporium extracts is reasonably strong — multiple double-blind placebo-controlled trials show significant symptom score reductions and reduced medication use. Evidence for Aspergillus and Penicillium SCIT is more limited. SCIT must be administered in a clinic setting with a 20–30 minute observation period due to the 0.1–0.2% systemic reaction risk per injection.
SLIT involves placing allergen extract drops or tablets under the tongue daily at home. While SLIT has excellent evidence for dust mite, grass pollen, and ragweed allergens (with FDA-approved tablet products available), the evidence base for mold SLIT is significantly weaker. No FDA-approved mold SLIT product currently exists in the United States, and off-label liquid mold SLIT is used by some allergists with variable standardization. European allergy societies have endorsed SLIT for Alternaria and Cladosporium with moderate evidence rating; AAAAI guidelines note insufficient evidence for routine recommendation.
A critical point that is frequently overlooked: immunotherapy for mold allergy has substantially lower response rates than immunotherapy for pollen or dust mite allergy when the patient continues to have ongoing high-level mold exposure in their home environment. The immunological tolerance induced by AIT can be overwhelmed by continuous antigen challenge. For this reason, AAAAI guidelines recommend that allergen source reduction — including professional mold remediation of the home environment — be implemented as a first-line intervention alongside or before AIT. Treating the body without treating the building is an incomplete response to mold allergy.
Understanding the temporal pattern of a patient's mold symptoms is important for both diagnosis and management. Outdoor mold-dominant species (Alternaria, Cladosporium, Drechslera) cause seasonal patterns tied to vegetation cycles. In the continental United States:
Patients with perennial (year-round) mold allergy symptoms — particularly those that are worse indoors, worse in specific rooms, or improve during travel — should be evaluated for indoor mold contamination as the primary exposure source. Our dehumidifiers for mold guide and whole-home mold prevention guide provide actionable indoor exposure reduction steps.
For children in affected households, the stakes are higher: early Alternaria sensitization is a strong predictor of persistent asthma. Our mold and children health guide covers pediatric-specific exposure thresholds and symptom patterns in detail.
The distinction between primarily outdoor and primarily indoor mold species has practical implications for avoidance counseling. Outdoor-dominant species (Alternaria, Cladosporium, Drechslera, Bipolaris) enter the home through open windows, HVAC systems without adequate pre-filtration, and on clothing and footwear. Mitigation strategies focus on keeping windows closed during high outdoor spore count days, using HEPA filtration in HVAC, and reviewing pollen/mold spore count data from the National Allergy Bureau (NAB) before outdoor activity.
Indoor-dominant species (Aspergillus, Penicillium, Stachybotrys, Chaetomium) grow on building materials inside the structure. Their presence at clinically significant levels almost always requires an active moisture source — plumbing leaks, condensation, flooding history, or inadequate vapor control in crawl spaces. Avoidance of these species requires source control: finding and fixing the moisture problem, then remediating the mold growth. Air filtration alone provides negligible benefit when active indoor growth continues to shed spores directly into the living environment. For HVAC-related mold exposure, our mold and HVAC guide covers duct contamination and filtration specifications.
Bedroom mold exposure is a particularly high-risk scenario because occupants spend 6–9 hours per night breathing in a small enclosed space where mold concentrations can be substantially higher than in other rooms. Our mold in bedroom guide addresses this high-exposure scenario. For the relationship between mold and sinus disease — one of the most common presenting complaints in mold-sensitized patients — see our mold and sinuses guide.
The single most evidence-supported intervention for indoor mold allergy is elimination of the indoor mold source. This is not controversial — the AAAAI, CDC, EPA, and WHO all state that mold-contaminated materials should be physically removed and moisture problems corrected as the primary response to mold-related illness. No antihistamine, corticosteroid spray, or immunotherapy protocol can substitute for removing the source that is driving ongoing sensitization and symptom production.
Professional mold remediation should be considered when: visible mold growth exceeds 10 square feet; mold is present in HVAC systems, crawl spaces, or wall cavities; occupants have symptoms consistent with mold sensitization; or DIY cleaning has failed to prevent recurrence. Our air purifiers for mold guide and mold testing guide help homeowners document their indoor mold burden before and after remediation. Renters have legal rights to mold-free housing in most states — see our resource on tenant rights for details.
A practical clue is the timing and location of symptoms. Pollen allergy symptoms peak during specific pollination seasons and are typically worse outdoors. Mold allergy symptoms that are consistently worse indoors, worse in a specific room (basement, bathroom), or present year-round without a clear seasonal pattern suggest indoor mold exposure. Confirmed diagnosis requires allergy testing — skin prick test or serum-specific IgE — by a board-certified allergist. If your allergy tests show mold sensitization and you have indoor symptoms, a professional mold inspection is warranted before starting immunotherapy.
Yes, though it is uncommon. Alternaria sensitization is the mold allergen most strongly linked to severe systemic allergic reactions, including life-threatening bronchospasm and cardiovascular collapse. The "thunderstorm asthma" phenomenon — documented fatal mass-casualty events from sudden high-concentration Alternaria exposure — represents the extreme end of this spectrum. Patients with Alternaria sensitization and co-existing asthma should discuss epinephrine auto-injector prescription with their allergist.
Subcutaneous immunotherapy (allergy shots) with Alternaria and Cladosporium extracts has moderate evidence of efficacy for reducing rhinitis and asthma symptoms. The evidence is strongest for Alternaria. Allergy shots are significantly less effective when ongoing high-level indoor mold exposure continues. For patients living in mold-contaminated homes, source remediation must accompany or precede immunotherapy for treatment to be meaningful.
Yes. The remediation process — demolition of affected materials, bagging and removal of mold-contaminated debris — releases high concentrations of mold spores and mycotoxins into the air. Professional remediation uses containment barriers and negative air pressure to protect the rest of the home, but mold-sensitized individuals and people with asthma should not be present in the building during active remediation work. Return is appropriate after post-remediation clearance testing confirms that indoor spore counts have returned to normal background levels.
